Pramipexole
Also known as: Prami, Mirapex, Mirapexin
Dopamine Agonist | Prolactin Management Alternative
Overview
Pramipexole is a non-ergoline dopamine agonist with preferential affinity for the D3 dopamine receptor subtype. It is FDA-approved under the brand names Mirapex and Mirapexin for the treatment of Parkinson's disease and restless legs syndrome (RLS). In the bodybuilding and performance enhancement context, pramipexole serves as an alternative to cabergoline for managing prolactin elevation caused by 19-nor anabolic steroids such as nandrolone (Deca-Durabolin, NPP) and trenbolone. While less potent than cabergoline at suppressing prolactin, pramipexole is typically cheaper and more readily available, making it a practical option when cabergoline is difficult to source. Its shorter half-life of approximately 8 hours necessitates daily dosing (usually at bedtime), and it must be titrated slowly from a low starting dose to minimize side effects -- particularly nausea, which is common during initiation. Pramipexole is generally considered a second-choice prolactin management agent behind cabergoline due to its lower potency, shorter duration, and less favorable side effect profile at the doses sometimes needed for adequate prolactin suppression.
Key benefits
- Suppresses prolactin elevation caused by 19-nor anabolic steroids
- Non-ergoline structure eliminates the risk of cardiac valve fibrosis associated with ergot-derived agents like cabergoline
- Generally cheaper and more widely available than cabergoline
- FDA-approved with a well-characterized safety and pharmacokinetic profile
- Can restore sexual function impaired by prolactin elevation on nandrolone or trenbolone cycles
- Viable alternative when cabergoline cannot be sourced
Mechanism of action
Pramipexole exerts its prolactin-suppressing effects by acting as a full agonist at dopamine D2 and D3 receptors, with a marked preference for the D3 subtype. In the anterior pituitary, prolactin secretion by lactotroph cells is tonically inhibited by hypothalamic dopamine acting on D2 receptors. Pramipexole stimulates these D2 receptors to suppress prolactin gene transcription, synthesis, and release. Its preferential D3 activity also contributes to its clinical effects in Parkinson's disease and may account for some of its neuropsychiatric side effects, particularly impulse control disorders, which are mediated through mesolimbic D3 signaling pathways. In the context of 19-nor steroid use, nandrolone and trenbolone elevate prolactin through progestogenic activity at the pituitary, and pramipexole counteracts this by restoring dopaminergic inhibition. However, because pramipexole has lower D2 affinity and a much shorter half-life than cabergoline, higher relative doses and more frequent administration are needed to achieve comparable prolactin suppression.
Molecular data
- Type
- Non-ergoline dopamine D3 receptor agonist
- Half-life
- ~8 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
19-Nor Compound Support
Medical Applications
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.125mg | Once daily at bedtime | — |
| — | 0.25mg | Once daily at bedtime | — |
| — | 0.5mg | Once daily at bedtime | — |
| — | 0.125-0.5mg | Once daily, 2-3 hours before bedtime | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nausea (very common during initiation; typically resolves with continued use)
- Drowsiness and somnolence (often taken at bedtime to manage this)
- Dizziness or lightheadedness
- Headache
- Insomnia (in some users, despite drowsiness being more typical)
- Orthostatic hypotension (feeling faint when standing up quickly)
Rare side effects
- Impulse control disorders (compulsive gambling, hypersexuality, binge eating, compulsive shopping -- more common than with cabergoline due to D3 receptor preference)
- Hallucinations and psychotic episodes (dose-dependent, more common in elderly Parkinson's patients)
- Sudden onset of sleep (sleep attacks without warning drowsiness)
- Peripheral edema
- Dyskinesia (primarily in Parkinson's patients on concurrent levodopa therapy)
Contraindications
- Known hypersensitivity to pramipexole or any component of the formulation
- Concurrent use of other dopamine agonists (cabergoline, bromocriptine)
- History of impulse control disorders or pathological gambling
- Severe renal impairment (pramipexole is primarily renally excreted; dose adjustment required in moderate impairment)
- Concurrent use of dopamine antagonists (antipsychotics, metoclopramide) which oppose pramipexole's mechanism
References
Primary literature and clinical-trial data informing this entry.